- Home
- ASMB vs AKYA Comparison
ASMB vs AKYA Comparison
Compare ASMB & AKYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- AKYA
- Stock Information
- Founded
- ASMB 2005
- AKYA 2015
- Country
- ASMB United States
- AKYA United States
- Employees
- ASMB N/A
- AKYA N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- AKYA Medical Specialities
- Sector
- ASMB Health Care
- AKYA Industrials
- Exchange
- ASMB Nasdaq
- AKYA Nasdaq
- Market Cap
- ASMB 84.5M
- AKYA 78.8M
- IPO Year
- ASMB 2010
- AKYA 2021
- Fundamental
- Price
- ASMB $10.92
- AKYA $1.51
- Analyst Decision
- ASMB Buy
- AKYA Buy
- Analyst Count
- ASMB 2
- AKYA 6
- Target Price
- ASMB $35.00
- AKYA $3.63
- AVG Volume (30 Days)
- ASMB 29.4K
- AKYA 374.9K
- Earning Date
- ASMB 03-27-2025
- AKYA 03-21-2025
- Dividend Yield
- ASMB N/A
- AKYA N/A
- EPS Growth
- ASMB N/A
- AKYA N/A
- EPS
- ASMB N/A
- AKYA N/A
- Revenue
- ASMB $28,326,000.00
- AKYA $86,815,000.00
- Revenue This Year
- ASMB $282.16
- AKYA N/A
- Revenue Next Year
- ASMB N/A
- AKYA $11.90
- P/E Ratio
- ASMB N/A
- AKYA N/A
- Revenue Growth
- ASMB N/A
- AKYA N/A
- 52 Week Low
- ASMB $10.56
- AKYA $1.43
- 52 Week High
- ASMB $19.93
- AKYA $5.25
- Technical
- Relative Strength Index (RSI)
- ASMB 33.39
- AKYA 30.21
- Support Level
- ASMB $10.56
- AKYA $1.52
- Resistance Level
- ASMB $13.07
- AKYA $1.69
- Average True Range (ATR)
- ASMB 0.72
- AKYA 0.13
- MACD
- ASMB -0.09
- AKYA 0.00
- Stochastic Oscillator
- ASMB 15.44
- AKYA 20.90
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.